February 5, 2021 07:02 AM ESTUpdated 07:45 AM

AstraZeneca's Imfinzi fails main OS endpoint in PhIII for head and neck cancer — and adding tremelimumab didn’t help, either

Amber Tong

When AstraZeneca reported disappointing results from the Phase III EAGLE trial, the company pointed to the KESTREL study — which tests its PD-L1 drug Imfinzi both …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca's Imfinzi fails main OS endpoint in PhIII for head and neck cancer — and adding tremelimumab didn’t help, either

Amber Tong

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

Biotech VC firm outlines plans for $100M fund

FDA OKs the first-ever self-administered vaccine, for flu

The drug lobby's lawsuit against the IRA finds a sign of life after appeals court ruling

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Breaking down silos with a new quantitative approach to drug development

As­traZeneca's Imfinzi fails main OS end­point in PhI­II for head and neck can­cer — and adding treme­li­mum­ab didn’t help, ei­ther

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

AstraZeneca's Imfinzi fails main OS endpoint in PhIII for head and neck cancer — and adding tremelimumab didn’t help, either